Stay updated with breaking news from Alpine Immune Sciences. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Ikena Oncology (NASDAQ:IKNA – Get Rating) and Adaptimmune Therapeutics (NASDAQ:ADAP – Get Rating) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, risk, profitability, valuation, dividends, institutional ownership and earnings. Risk and Volatility Ikena Oncology has a beta of […]
Wall Street analysts expect that Alpine Immune Sciences, Inc. (NASDAQ:ALPN – Get Rating) will post sales of $13.35 million for the current quarter, Zacks Investment Research reports. Three analysts have made estimates for Alpine Immune Sciences’ earnings, with estimates ranging from $5.93 million to $20.00 million. Alpine Immune Sciences posted sales of $3.20 million in […]
/PRNewswire/ -- The "Gene Therapies & Associated Vectors: Intellectual Property Landscape" report has been added to ResearchAndMarkets.com's offering. Although...
- Alpine to hold Investor Event on Tuesday, April 12th at 6:00pm ET - ... | March 30, 2022
Alpine Immune Sciences, Inc. (NASDAQ:ALPN – Get Rating) – Stock analysts at Wedbush issued their Q1 2022 earnings per share (EPS) estimates for shares of Alpine Immune Sciences in a research note issued to investors on Monday, March 21st. Wedbush analyst R. Driscoll anticipates that the biotechnology company will earn ($0.27) per share for the […]